Founder and lead investor ARCH Venture Partners is joined by NVIDIA's NVentures, Menlo Ventures, and Madrona Funding accelerates advancement of Vilya's proprietary computational drug design and development platform and its pipeline of novel macrocycles that precisely target disease biology Vilya's foundational technology leverages advanced computational approaches to design novel macrocycles with atomic-level accuracy and enhanced drug-like properties SEATTLE, June 04, 2024 (GLOBE NEWSWIRE) -- VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, announced today an expanded $71 million Series A financing. Founder and lead investor ARCH Venture Partners is joined by leading life science and technology funds, including NVIDIA's venture capital arm NVentures, Menlo Ventures, Madrona, Lifeforce Capital, and Altitude Life Science Ventures. "The support of these high-caliber investors will help us significantly enhance our generative AI platform, broadening the diversity of macrocycles we are able to design, synthesize and develop, in addition to broadening the targets we can design against," said Cyrus Harmon, Ph.D., Chief Executive Officer at Vilya. "This funding also extends our ability to rapidly advance our designed macrocycles to clinical development ...